Elsevier

Journal of Hepatology

Volume 44, Issue 3, March 2006, Pages 593-606
Journal of Hepatology

Review
HBV drug resistance: Mechanisms, detection and interpretation

https://doi.org/10.1016/j.jhep.2006.01.001Get rights and content

Introduction

Besides interferon, only two drugs—lamivudine and adefovir dipivoxil—are approved as first-line therapy for chronic hepatitis B (CHB) in the EU [1], [2]. Each is a nucleoside or nucleotide analogue that acts mainly as a specific inhibitor of the viral polymerase/reverse transcriptase (for convenience, the acronym Nucleos(t)ide Reverse Transcriptase Inhibitor (NRTI) will be used here to refer all nucleoside and nucleotide derivatives that act by inhibiting functions of the HBV polymerase). Several other NRTIs besides lamivudine and adefovir dipivoxil have been found to be effective against HBV [1]. They include entecavir, which is licensed in the USA [3], and tenofovir, which is used to treat HIV-1 infection [4], [5]. In most cases, treatment of CHB with any single NRTI produces rapid suppression of HBV replication in the short-term, an effect that is not often sustainable due to the emergence of drug-resistant HBV strains [1], [6]. Although a variety of other factors including adverse short-term side effects, long-term toxicity, previous sub-optimal treatment regimes, inadequate drug exposure (due to pharmacological properties of particular drugs, poor patient compliance with prescribed treatment, or host genetic polymorphisms) influence the efficacy of treatments for chronic HBV, drug resistance is emerging as the single most significant factor in treatment failure [7]. Failure of NRTI treatment presents a significant clinical challenge, because remaining treatment options are limited [2], [8]. Here, we attempt to summarise the current state of knowledge of HBV resistance to NRTI, briefly describe available methods for detecting and quantifying drug resistance and discuss the interpretation of drug resistance and its clinical applications.

Resistance can be defined in technical, virological or clinical terms. Technically, resistance is defined by either (1) a statistically significant change in the test parameter (increase in EC50, for example) or (2) the minimum change in a parameter that is required for statistical significance (for example, a single log10 change). Technical definitions only describe the attributes of specific tests and have no biological or clinical significance.

Virological resistance is now commonly described as high-, intermediate- or low-level based on fold-changes in EC50 in vitro. Such ranking, unfortunately, does not relate directly to clinical observations. For example, lamivudine failure is associated with >100 fold increase in EC50 in vitro, but HBV isolates responsible for adefovir resistance exhibit only low-level (<10-fold increase in) resistance in vitro.

Clinical resistance is most easily defined in terms of viral load fluctuations (based on results of assays for serum HBV DNA), which are currently the best available indicators of HBV replication in vivo. The following definitions have been proposed as a basis for further development [8]. An antiviral effect is defined as a minimum reduction in serum HBV DNA of 1 log10 IU/mL from the pre-treatment baseline within the first 3 months. Failure to achieve this decrease constitutes primary treatment failure. A confirmed increase in serum HBV DNA of 1 log10 IU/mL from the nadir following initially effective treatment constitutes secondary treatment failure. Genotyping and/or phenotyping of clinical isolates are required to confirm that treatment failure is due to resistant virus (see Fig. 1, Fig. 2).

Section snippets

Resistance to NRTI

Resistance and cross-resistance to NRTIs is more or less structure-specific. Anti-HBV NRTIs can be separated into three main structural groups (see Fig. 3 and Table 1).

  • (1)

    l-Nucleoside analogues, including lamivudine, its 5-fluoro-derivative emtricitabine, telbivudine (l-thymidine), torcitabine (l-deoxycytidine) and clevudine (l-FMAU).

  • (2)

    Acyclic nucleoside phosphonates, represented by the dAMP analogues adefovir and tenofovir, together with others that have reached late stage clinical trials.

  • (3)

Molecular modelling identifies mechanisms for resistance to NRTI

Laboratory studies of mechanisms for HBV resistance to NRTI have been frustrated by the inability to obtain sufficient quantities of purified polymerase. However, it has been possible to create three-dimensional models of the reverse transcriptase (rt) region of HBV polymerase have based on its homology with related polymerases, including HIV-1 rt. Using these models, the amino acid changes resulting from mutations that confer antiviral resistance can be mapped to functional regions to provide

Detection of drug resistance

A variety of different methods for detection, and in some cases, quantification, of drug resistance in HBV are now available, but they need to be improved and standardized, as interpretation and comparison of drug resistance data obtained by different methods is currently difficult and contentious. Drug resistant HBV can be detected by genotyping and/or phenotyping. Only the latter provides direct measurements of in vitro resistance to specific drugs, but each approach has inherent advantages

Interpretation of genotypes and phenotypes

Prediction of phenotypes from genotypes is likely to be difficult when multiple resistance and compensatory mutations are present, a situation that is common in HBV isolates from individuals who have been treated for long periods with a variety of antiviral drugs. Rather than being dichotomous, antiviral resistance and susceptibility are extremes of a continuous variable that is modified by, and modifies, replication fitness. The major advantage of phenotyping is that it provides quantitative

Resistance testing for treatment optimisation

As more drugs become available and databases such as SeqHepB continue to expand, resistance testing is likely to guide therapeutic decision-making for all treatment-experienced CHB patients [36]. The probability of primary antiviral resistance occurring by transmission, although low, is not negligible, so suppressing apparently ‘benign’ replication-deficient multi-drug resistant mutants in experienced patients may be necessary. Designing new regimes that have the greatest chance of achieving

Preventing drug resistance and management of NRTI-resistant infection

There are three main ways to minimise development and spread of drug resistance: (1) avoiding unnecessary therapy, (2) careful choice therapy and (3) continuous surveillance for drug resistance.

Conclusions

Ideally, treatment for HBV infection should begin at diagnosis, but this is not yet feasible because of limitations of existing drugs. Ongoing clinical trials and concurrent improvements in diagnostic technology guarantee that treatment options and opinions on patient management will continue to evolve. Problems caused by cross-resistance may eventually be solved by the introduction of antiviral drugs that block stages of the viral life cycle distinct from those inhibited by NRTIs, but such

First page preview

First page preview
Click to open first page preview

References (111)

  • P. Punia et al.

    Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR

    J Hepatol

    (2004)
  • S.D. Pas et al.

    Quantification of the newly detected lamivudine resistant YSDD variants of hepatitis B virus using molecular beacons

    J Clin Virol

    (2005)
  • H. Yang et al.

    In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector

    Antiviral Res

    (2004)
  • R.Y. Chen et al.

    Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

    Hepatology

    (2003)
  • O. Gallego et al.

    Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals

    J Virol Methods

    (2004)
  • E.B. Keeffe et al.

    A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

    Clin Gastroenterol Hepatol

    (2004)
  • D.D. Richman

    The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B

    Hepatology

    (2000)
  • M.G. Peters et al.

    Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

    Gastroenterology

    (2004)
  • T. Shaw et al.

    Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?

    Gastroenterology

    (2004)
  • U. Mihm et al.

    Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy

    J Hepatol

    (2005)
  • M. Maynard et al.

    Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure

    J Hepatol

    (2005)
  • M. Buti et al.

    Drugs in development for hepatitis B

    Drugs

    (2005)
  • Craxi A, Antonucci G, Camma C. Treatment options in HBV. J Hepatol 2006; 44(Suppl 1):...
  • T. Shaw et al.

    Entecavir for the treatment of chronic hepatitis B

    Expert Rev Anti Infect Ther

    (2004)
  • C.L. Thio et al.

    Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box

    Clin Infect Dis

    (2005)
  • M.E. Mailliard et al.

    Emerging therapeutics for chronic hepatitis B

    Annu Rev Med

    (2005)
  • Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:...
  • S. Locarnini et al.

    Management of antiviral resistance in patients with chronic hepatitis B

    Antivir Ther

    (2004)
  • O. Lada et al.

    In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir

    Antivir Ther

    (2004)
  • M.N. Brunelle et al.

    Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir

    Hepatology

    (2005)
  • H. Yang et al.

    Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV

    Antivir Ther

    (2005)
  • D.J. Tenney et al.

    Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

    Antimicrob Agents Chemother

    (2004)
  • K. Das et al.

    Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC)

    J Virol

    (2001)
  • A. Bartholomeusz et al.

    Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations

    Antivir Ther

    (2004)
  • A. Bartholomeusz et al.

    Mechanistic basis for hepatitis B virus resistance to acyclic phosphonate analogues, adefovir and tenofovir. (Abstract 1011)

    Hepatology

    (2005)
  • Y. Benhamou et al.

    Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

    Hepatology

    (1999)
  • M.I. Allen et al.

    Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

    Hepatology

    (1998)
  • W.E. Delaney et al.

    The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro

    J Virol

    (2003)
  • H. Nakanishi et al.

    Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B

    Intervirology

    (2005)
  • S.B. Pai et al.

    Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy

    Antimicrob Agents Chemother

    (2005)
  • Y. Chong et al.

    Mechanism of antiviral activities of 3′-substituted l-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach

    Antivir Chem Chemother

    (2003)
  • M. Melegari et al.

    Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

    Hepatology

    (1998)
  • S.K. Ono et al.

    The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

    J Clin Invest

    (2001)
  • Y.B. Hong et al.

    Increased DNA polymerase fidelity of the Lamivudine resistant variants of human hepatitis B virus DNA polymerase

    J Biochem Mol Biol

    (2004)
  • N. Ogata et al.

    Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B

    J Med Virol

    (1999)
  • Y.-S. Lee et al.

    Hepatitis B virus with rtL80V/I mutation associates with poor response to adefovir dipivoxil therapy (Abstract 965)

    Hepatology

    (2005)
  • C.T. Yeh et al.

    Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

    Hepatology

    (2000)
  • R.G. Gish

    Clinical trial results of new therapies for HBV: implications for treatment guidelines

    Semin Liver Dis

    (2005)
  • M.F. Yuen et al.

    Adefovir dipivoxil in chronic hepatitis B infection

    Expert Opin Pharmacother

    (2004)
  • S.J. Hadziyannis et al.

    Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B

    N Engl J Med

    (2005)
  • Cited by (196)

    • Molecular and computational analysis of natural drug resistance mutations among Moroccan chronic hepatitis B carriers

      2021, Gene Reports
      Citation Excerpt :

      Primary drug resistance mutations confer reduced intrinsic susceptibility to chemotherapeutic agents. In viruses, secondary mutations are known to correct replication defects resulting from primary resistance (Lok et al., 2007; Shaw et al., 2006). However, the impact of the non-classical resistance mutations on NA treatment is not yet clear.

    View all citing articles on Scopus
    View full text